3,845 Shares in Solventum Co. (NYSE:SOLV) Purchased by Kennondale Capital Management LLC

Kennondale Capital Management LLC purchased a new position in shares of Solventum Co. (NYSE:SOLVFree Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 3,845 shares of the company’s stock, valued at approximately $254,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Modus Advisors LLC acquired a new stake in Solventum during the fourth quarter worth about $25,000. Stonebridge Financial Group LLC acquired a new stake in shares of Solventum in the fourth quarter valued at about $26,000. True Wealth Design LLC grew its stake in shares of Solventum by 23,550.0% in the third quarter. True Wealth Design LLC now owns 473 shares of the company’s stock valued at $33,000 after buying an additional 471 shares in the last quarter. Crews Bank & Trust acquired a new stake in shares of Solventum in the fourth quarter valued at about $32,000. Finally, Prospera Private Wealth LLC acquired a new stake in shares of Solventum in the third quarter valued at about $35,000.

Solventum Trading Up 1.2 %

NYSE:SOLV opened at $75.04 on Tuesday. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. The business’s 50 day moving average is $74.65 and its two-hundred day moving average is $71.30. Solventum Co. has a 52 week low of $47.16 and a 52 week high of $85.92. The company has a market cap of $12.98 billion and a PE ratio of 27.29.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on SOLV. Mizuho increased their target price on Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a research note on Monday, March 3rd. Piper Sandler increased their target price on Solventum from $75.00 to $84.00 and gave the company a “neutral” rating in a research note on Friday, February 28th. Morgan Stanley increased their target price on Solventum from $73.00 to $80.00 and gave the company an “equal weight” rating in a research note on Wednesday, March 5th. Bank of America increased their target price on Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a research note on Wednesday, February 26th. Finally, The Goldman Sachs Group increased their price target on Solventum from $63.00 to $71.00 and gave the company a “sell” rating in a report on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and one has given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $79.86.

Get Our Latest Analysis on Solventum

About Solventum

(Free Report)

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.

Featured Stories

Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Co. (NYSE:SOLVFree Report).

Institutional Ownership by Quarter for Solventum (NYSE:SOLV)

Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.